Mindfulness-Based fMRI Neurofeedback for Depression

Launched by COLUMBIA UNIVERSITY · Nov 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for depression in adolescents that combines mindfulness and brain imaging technology called fMRI neurofeedback. The goal is to see if this innovative method can help reduce negative thinking patterns, known as rumination, which often make depression worse. By changing how the brain responds during moments of rumination, researchers hope to improve mental health outcomes for young people struggling with major depression.

To participate in this study, individuals must be between 13 and 18 years old, have a diagnosed case of major depressive disorder (MDD), and be able to speak and understand English. Parents or guardians must also give permission for those aged 13 to 17. Participants will be closely monitored and can expect to engage in mindfulness exercises while their brain activity is recorded. It’s important to note that individuals with certain mental health conditions, specific medical issues, or those currently taking certain medications will not be eligible for this trial. This study is currently recruiting participants, aiming to provide new hope for adolescents facing depression.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ages 13-18 years-old
• • Written informed assent/consent and parental/guardian permission for 13-17 year-olds or informed consent for 18 year-olds
• • Tanner puberty stage ≥3
• • Meets current diagnostic criteria for MDD
• • English fluency
• Exclusion Criteria:
• • Lifetime history of primary psychotic disorders, bipolar disorder, oppositional defiant disorder, conduct disorder, developmental disorder (e.g., autism), post-traumatic stress disorder, or eating disorders
• • Substance use disorder, moderate or severe in past 6 months
• • Active suicidal ideation with a specific plan
• • History of seizure disorder
• • Medical or neurological illness (e.g., severe head injury)
• • MRI contraindications
• • Current psychotropic medication use other than antidepressant medication
• • Intelligence quotient (IQ) \<80.